乳腺钼靶乳腺影像报告和数据系统分类诊断早期乳腺癌的效能分析

Objective To evaluate the diagnostic efficacy and clinical value of the mammography breast imagingreporting and data system(BI-RADS) classification in early breast cancer screening. Methods A total of 80 patients with suspected breast lesions treated from March 2021 to June 2025 were included. All underwent mammography and BI-RADS assessment. Pathology served as the gold standard. Malignancy rates for each BI-RADS category and diagnostic indicators including sensitivity, specificity, accuracy, positive predictive value(PPV), and negative predictive value(NPV) were calculated. Results Among 80 patients, 29 were diagnosed with breast cancer and 51 with benign lesions. BI-RADS distribution: category 1(0 cases), 2(25 cases), 3(18 cases), 4(37 cases). Malignancy rates were 0.00% for category 2, 11.11% for category 3, and 72.97% for category 4. The BI-RADS classification system demonstrated a sensitivity of 93.10%, specificity of 80.39%, accuracy of 85.00%, PPV of 72.97%, and NPV of 95.35% for diagnosing early stage breast cancer. Conclusion The mammography BI-RADS classification demonstrates high diagnostic efficacy for early breast cancer and provides reliable guidance for clinical management.